Allergan, Inc. (NYSE: AGN)
Irvine, CA 92612 (Map) Phone: 714-246-4500
Fax: 714-246-6987
Toll Free: 800-347-4500
http://www.allergan.com
Overview
Don't let the name fool you, Allergan can't help you with that runny nose. Instead, the company is a leading maker of eye care, skin care, and aesthetic products, including best-selling pharmaceutical Botox. Originally used to treat muscle spasms (as well as eye spasms and misalignment), Botox found another, more popular application in diminishing facial wrinkles. Allergan's eye care products include medications for glaucoma, allergic conjunctivitis, and chronic dry eye. Skin care products include treatments for acne, wrinkles, and psoriasis. Allergan also sells implants used in breast augmentation and weight-loss surgery. Its products are sold in 100 countries via direct sales and distributors.
Sample Overview & HistoryKey Numbers from Hoover's UK
Key financials for Allergan, Inc. (NYSE: AGN)
| Company Type | Public (NYSE: AGN) |
|---|---|
| Fiscal Year-End | December |
| 2010 Sales (mil.) | £3,179.9 |
| 1-Year Sales Growth | 9.2% |
| 2010 Net Income (mil.) | £0.4 |
| 1-Year Net Income Growth | (99.9%) |
| 2010 Employees | 9,200 |
| 1-Year Employee Growth | 10.8% |
Key People from Hoover's UK
Key people and executives for Allergan, Inc. (NYSE: AGN)
| Chairman Emeritus | Gavin S. Herbert (Subscribers see complete biographies -- view sample)
|
|---|---|
| Chairman, President, and CEO | David E. I. Pyott |
| EVP Finance and Business Development and CFO | Jeffrey L. Edwards |
Top Competitors from Hoover's UK
Top competitors of Allergan, Inc. (NYSE: AGN)
There are 25 competitors for Allergan; see more.Industry Information from Hoover's UK
First Research Industry Profiles Extensive Industry Intelligence
Hoover's Industries
- Pharmaceuticals(primary)
Subsidiaries/Affiliates Covered By Hoover's UK
Subsidiaries/affiliates of Allergan, Inc. (NYSE: AGN)
Rankings from Hoover's UK
See how Allergan, Inc. (NYSE: AGN) ranks in standard industry listings such as Fortune 500, S&P 500, and Dow Jones
- #457 in FORTUNE 500 (May 2011)
- S&P 500
- #457 in FORTUNE 1000 (May 2011)
- #426 in FT Global 500 (June 2011)

